The current state of preclinical prostate cancer animal models Journal Article


Authors: Pienta, K. J.; Abate-Shen, C.; Agus, D. B.; Attar, R. M.; Chung, L. W. K.; Greenberg, N. M.; Hahn, W. C.; Isaacs, J. T.; Navone, N. M.; Peehl, D. M.; Simons, J. W.; Solit, D. B.; Soule, H. R.; VanDyke, T. A.; Weber, M. J.; Wu, L.; Vessella, R. L.
Article Title: The current state of preclinical prostate cancer animal models
Abstract: Prostate cancer continues to be a major cause of morbidity and mortality in men around the world. The field of prostate cancer research continues to be hindered by the lack of relevant preclinical models to study tumorigenesis and to further development of effective prevention and therapeutic strategies. The Prostate Cancer Foundation held a Prostate Cancer Models Working Group (PCMWG) Summit on August 6th and 7th, 2007 to address these issues. The PCMWG reviewed the state of prostate cancer preclinical models and identified the current limitations of cell line, xenograft and genetically engineered mouse models that have hampered the transition of scientific findings from these models to human clinical trials. In addition the PCMWG identified administrative issues that inhibit the exchange of models and impede greater interactions between academic centers and these centers with industry. The PCMWG identified potential solutions for discovery bottlenecks that include: (1) insufficient number of models with insufficient molecular and biologic diversity to reflect human cancer, (2) a lack of understanding of the molecular events that define tumorigenesis, (3) a lack of tools for studying tumor-host interactions, (4) difficulty in accessing model systems across institutions, and (5) addressing why preclinical studies appear not to be predictive of human clinical trials. It should be possible to apply the knowledge gained molecular and epigenetic studies to develop new cell lines and models that mimic progressive and fatal prostate cancer and ultimately improve interventions. © 2008 Wiley-Liss, Inc.
Keywords: review; nonhuman; mouse; animals; mice; cancer prevention; morbidity; cell line; animal model; genetic variability; drug screening assays, antitumor; cell line, tumor; cancer mortality; carcinogenesis; mice, transgenic; prostate cancer; prostatic neoplasms; genetic engineering; xenograft; epigenetics; neoplasms, experimental; disease models, animal; university hospital; biodiversity; cell lines; genetically engineered
Journal Title: Prostate
Volume: 68
Issue: 6
ISSN: 0270-4137
Publisher: John Wiley & Sons  
Date Published: 2008-05-01
Start Page: 629
End Page: 639
Language: English
DOI: 10.1002/pros.20726
PUBMED: 18213636
PROVIDER: scopus
PMCID: PMC3681409
DOI/URL:
Notes: --- - "Cited By (since 1996): 21" - "Export Date: 17 November 2011" - "CODEN: PRSTD" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David Solit
    779 Solit